Looking to build a ‘dual sourcing’ supply chain, WuXi Biologics shells out $183M for Bayer drug substance plant – Endpoints News
Biologics have been particularly hot in 2020 with big drugmakers looking to bolster their portfolio — a trend that has been a serious boon for...

